Jacobson L P, Kirby A J, Polk S, Phair J P, Besley D R, Saah A J, Kingsley L A, Schrager L K
Johns Hopkins University, School of Public Health, Department of Epidemiology, Baltimore, MD 21205.
Am J Epidemiol. 1993 Dec 1;138(11):952-64. doi: 10.1093/oxfordjournals.aje.a116815.
In a prospective cohort of 2,647 human immunodeficiency virus type 1 (HIV-1) seropositive homosexual men enrolled in Baltimore, Chicago, Los Angeles, and Pittsburgh, 891 developed clinical acquired immunodeficiency syndrome (AIDS) between June 1984 and January 1992. Cox proportional hazards models were used to examine temporal trends in survival after AIDS for specific diagnoses, controlling for level of immunosuppression at diagnosis, age, race, and geographic location. Median survival time following AIDS onset increased from 11.6 months in 1984-1985 to 19.5 months in 1988-1989; for those diagnosed in 1990-1991, the median survival time dropped to 17.2 months. Trends in improved survival were diagnosis-specific. Survival after Pneumocystis carinii pneumonia consistently improved from 1984 to 1991 (p < 0.001). Compared with men diagnosed in 1984-1985, those diagnosed with P. carinii pneumonia in 1990-1991 had one-tenth the hazard of dying. For men with > or = 100 helper T-lymphocytes (CD4+ cells) when diagnosed with Kaposi's sarcoma, the relative hazards (95% confidence intervals) of dying after Kaposi's sarcoma were 0.8 (0.42-1.60) in 1986-1987, 0.7 (0.34-1.58) in 1988-1989, and 0.6 (0.19-1.61) in 1990-1991 compared with those diagnosed before 1986. Men with < 100 CD4+ cells when diagnosed with Kaposi's sarcoma did not demonstrate a consistent change in their subsequent survival. After a nonsignificant (p > 0.05) initial improvement in prognosis, there has not been a significant improvement in survival for men who presented with other opportunistic infections. Observed increases in overall survival probably relate to improved treatment of patients who develop P. carinii pneumonia. Limited improvement in survival following other AIDS diagnoses indicates the need for developing effective treatment against these diseases.
在巴尔的摩、芝加哥、洛杉矶和匹兹堡招募的2647名1型人类免疫缺陷病毒(HIV-1)血清阳性同性恋男性的前瞻性队列研究中,891人在1984年6月至1992年1月期间发展为临床获得性免疫缺陷综合征(AIDS)。采用Cox比例风险模型来研究特定诊断的AIDS患者生存时间的时间趋势,同时控制诊断时的免疫抑制水平、年龄、种族和地理位置。AIDS发病后的中位生存时间从1984 - 1985年的11.6个月增加到1988 - 1989年的19.5个月;对于1990 - 1991年诊断的患者,中位生存时间降至17.2个月。生存改善趋势因诊断而异。1984年至1991年,卡氏肺孢子虫肺炎后的生存情况持续改善(p < 0.001)。与1984 - 1985年诊断的男性相比,1990 - 1991年诊断为卡氏肺孢子虫肺炎的男性死亡风险为十分之一。对于诊断为卡波西肉瘤时辅助性T淋巴细胞(CD4 + 细胞)≥100的男性,1986 - 1987年、1988 - 1989年和1990 - 1991年卡波西肉瘤后死亡的相对风险(95%置信区间)分别为0.8(0.42 - 1.60)、0.7(0.34 - 1.58)和0.6(0.19 - 1.61),与1986年前诊断的男性相比。诊断为卡波西肉瘤时CD4 + 细胞<100的男性在随后的生存中未表现出一致的变化。在预后有不显著(p > 0.05)的初步改善后,出现其他机会性感染的男性生存情况没有显著改善。观察到的总体生存改善可能与卡氏肺孢子虫肺炎患者治疗的改善有关。其他AIDS诊断后生存的有限改善表明需要开发针对这些疾病的有效治疗方法。